A

Agenus
D

AGEN

4.69000
USD
-0.13
(-2.70%)
مغلق
حجم التداول
13,321
الربح لكل سهم
2
العائد الربحي
-
P/E
0
حجم السوق
128,585,027
أصول ذات صلة
ACI
ACI
-0.160
(-0.75%)
21.220 USD
AEE
AEE
-1.520
(-1.56%)
95.660 USD
A
AGNC
-0.10500
(-1.12%)
9.30000 USD
ARGX
ARGX
-8.65
(-1.48%)
577.34 USD
المزيد
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).